Latest Biopolis Stories

SINGAPORE, April 9, 2013 /PRNewswire/ -- State-of-the-art laboratory focused on developing new, improved formulations for added patient benefit GlaxoSmithKline (GSK) and A*STAR's Institute of Chemical and Engineering Sciences (ICES) have signed a five-year strategic agreement to develop new evidence based formulations (EBFs) specifically for emerging markets. EBFs are medicines which are reformulated to provide additional patient benefit. ICES has a long standing...

R&D raises the competitiveness of the Singapore economy and drives productivity and growthSingapore, Dec 14, 2012 - (ACN Newswire) - Singapore's gross expenditure on R&D (GERD)[1] recorded a new high of S$7.4 billion in 2011, according to the National Survey of R&D, 2011, produced by the Agency for Science, Technology and Research (A*STAR). It was a 14.8% growth from S$6.5 billion in 2010.The compound annual growth rate (CAGR) of GERD from 2002 to 2011 was...

- Stratified medicine programme: deliver the right therapy to the right patient at the right time- Eye research: new clinical therapies to cure major eye diseases like glaucoma, corneal disease.Singapore, Nov 9, 2012 - (ACN Newswire) - Singapore announces 8 biomedical sciences research programmes to advance understanding and treatment of diseases especially prevalent amongst the Asian population. These programmes will see biomedical scientists and clinicians working...

Singapore, Nov 6, 2012 - (ACN Newswire) - In a latest boost to A*STAR's collaborations with the industry, Dr Bing LIM, Associate Director of Cancer Stem Cell Biology, and Senior Group Leader at the Genome Institute of Singapore (GIS), was recently awarded a GlaxoSmithKline (GSK) grant under the Academic Centre of Excellence(1) (ACE) to further his research on lung cancer at the GIS.This partnership between GIS and GSK, a multinational pharmaceutical, biologics, vaccines and consumer...

Singapore, July 16, 2012 - (ACN Newswire) - Scientists at A*STAR's Singapore Immunology Network (SIgN), in collaboration with Newcastle University, UK, the Singapore Institute of Clinical Sciences and clinicians from multiple hospitals in Singapore, have identified a new subset of dendritic cells (DCs) in human peripheral tissue which have a critical role in activating our immune response against harmful pathogens. This research will have significant impact on the design of vaccines and other...

Singapore, July 4, 2012 - (ACN Newswire) - A*STAR scientists from the Institute of Molecular and Cell Biology (IMCB) and the Singapore Bioimaging Consortium (SBIC) have discovered a new signalling pathway that controls both obesity and atherosclerosis. The team demonstrated, for the first time, that mice deficient in the Wip1 gene were resistant to weight gain and atherosclerosis via regulation of the Ataxia telangiectasia mutated gene (ATM) and its downstream signalling molecule mTor. These...

CHICAGO, May 4 /PRNewswire/ -- Singapore's integrated research network that offers multidisciplinary capabilities across basic and translational research has drawn pharmaceutical and biotech companies that seek to improve R&D decision making and accelerate innovation in Asia. The Biopolis' expansion is a key initiative amongst many to meet companies' rising need to capitalize on Asia's growth story. "Leveraging Singapore's close-knit research community and clinical research...

World's first photochromic contact lens that darken with sunlight exposure among Institute of Bioengineering and Nanotechnology advancesMarking a significant bench to bedside research milestone in Singapore, the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, and the National University Hospital (NUH) launched the IBN iCare and the NUH Eye Centre @ Biopolis at an official opening ceremony officiated by the Senior...

ATLANTA, May 19 /PRNewswire-Asia/ -- Leading pharmaceutical and biotech companies are drawing on Singapore's integrated network of public-sector and academic institutes to enhance their R&D productivity, leverage academic insights and diversify risks. Located at the heart of Asia with a population base that is representative of key Asian ethnic groups, Singapore provides a home-base of innovation for companies to test and develop new solutions for Asia and beyond. Recent...

SINGAPORE, Jan. 20 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced the opening of a new pharmaceutical analytical research laboratory in Singapore's Biopolis research park. This new facility, Abbott's first pharmaceutical research and development site in Southeast Asia, will conduct stability studies, including studies on active pharmaceutical ingredients and novel formulations, to support global regulatory requirements for new pharmaceutical products. The work done at the...